Evidence map›Paper›PMID 39480074›Full record

ArticleAntimicrobial agents and chemotherapy2024

Hadas Kon, Mor N Lurie-Weinberger, Moshe Bechor, Elizabeth Temkin, Ophir Kastel, David Schwartz, Alona Keren-Paz, Yehuda Carmeli, CRPA Working Group

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Emergence of outbreak-driving high-riskMicrobial genomics · 2026
    Article
  2. Article
  3. Risk prediction of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hadas Kon *National Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.
Mor N Lurie-Weinberger *National Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.
Moshe BechorNational Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.
Elizabeth TemkinNational Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.ORCID 0000-0001-6028-5819
Ophir KastelNational Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.
David SchwartzNational Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.
Alona Keren-PazNational Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.ORCID 0000-0002-0679-3967
Yehuda CarmeliNational Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv, Israel.
CRPA Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenem-resistant

Indexed as

Anti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsMicrobial Sensitivity TestsPseudomonas aeruginosaPseudomonas InfectionsCephalosporinsDrug Resistance, Multiple, BacterialHospitalsHumansIsraelPorinsTazobactamTobramycinWhole Genome SequencingAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsceftolozane, tazobactam drug combinationCephalosporinsOprD protein, Pseudomonas aeruginosaPorinsTazobactamTobramycinantimicrobial resistancecarbapenemasePseudomonas aeruginosasurveillancewhole-genome sequencing

Identifiers

PMID39480074
PMCPMC11619238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.